Major associations of drug manufacturers operating in EAEU member states announced the establishment of Eurasian Pharmaceutical Alliance (EAFA), a strategic partnership.
The main goal of EAFA will be to optimize the collaboration between the regulators, manufacturers, and distributors operating in EAEU countries. The Alliance can be joined by any pharmaceutical association operating in Armenia, Russia, Kazakhstan, Kyrgyzstan, and Belarus.
“Today, we established the most representative regional industry platform that united major pharmaceutical associations in the member states of Eurasian Economic Union, the activities of which are based on such fundamental principles as complying with high ethical standards enshrined in the relevant Codes of the Parties, protecting intellectual property rights, and promoting innovative development of health care systems in our countries,” said Vladimir Shipkov, the Executive Director of the Association of International Pharmaceutical Manufacturers.
The common pharmaceutical market of the EAEU began to operate officially on May 6, 2017, after the completion of all internal ratification procedures by EAEU member states and the enactment of basic regulatory document package for the drug circulation within EAEU. This created all prerequisites for launching the common market of medicinal products in the Eurasian Economic Union.